Video Experimental Relacionado
Updated: Feb 12, 2026
10:35
Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
37.2K
Un hombre de unos 60 años con inmunodeficiencia y hepatitis
Caroline Hvitmyhr1, Kristin Fjeldstad Enga2, Joakim Øverbø3
1Medisinsk avdeling, Ringerike sykehus, Vestre Viken.
Resumen
El aumento de las enzimas hepáticas en pacientes inmunocomprometidos puede deberse a diversas infecciones. Las pruebas de ácido nucleico son cruciales para diagnosticar el virus de la hepatitis E (VHE) en esta población.
Área de la Ciencia:
- Hepatología Hepatología.
- Inmunología Inmunología.
- Enfermedades infecciosas Enfermedades infecciosas.
Sus antecedentes:
- Las enzimas hepáticas elevadas tienen múltiples causas que incluyen enfermedades tóxicas, infecciosas, neoplásicas y autoinmunes.
- Los pacientes inmunocomprometidos presentan un espectro más amplio de patógenos de la hepatitis infecciosa con una respuesta inmune embotada, lo que complica el diagnóstico.
Objetivo del estudio:
- Para resaltar los desafíos de diagnóstico de la hepatitis en pacientes inmunocomprometidos.
- Hacer hincapié en la importancia de los enfoques de diagnóstico específicos para el virus de la hepatitis E (VHE) en las poblaciones en riesgo.
Principales métodos:
- Presentación del caso de un paciente sometido a terapia CAR-T para el mieloma múltiple.
- Discusión de estrategias de diagnóstico para la hepatitis infecciosa en individuos inmunocomprometidos.
Principales resultados:
- La hepatitis E es una infección poco diagnosticada que se puede contraer en Noruega.
- Las pruebas serológicas para el VHE pueden ser poco confiables en pacientes inmunocomprometidos.
Conclusiones:
- Los pacientes inmunocomprometidos tienen un mayor riesgo de hepatitis E crónica.
- La prueba de ácido nucleico para el ARN del HEV es el enfoque de diagnóstico primario recomendado para el HEV en pacientes inmunocomprometidos.
Videos de Conceptos Relacionados
01:25Immunodeficiency Diseases
2.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
2.5K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:21Hepatic Portal System
6.3K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
248
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
01:16Hepatic Drug Excretion: Influencing Factors
599
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
599
01:14Hepatic Drug Clearance: Role of Transporters
311
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
311